Precision BioSciences (NASDAQ:DTIL) Posts Earnings Results, Beats Expectations By $0.57 EPS

Precision BioSciences (NASDAQ:DTIL) issued its quarterly earnings results on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.57, reports. Precision BioSciences had a negative return on equity of 52.82% and a negative net margin of 96.73%.

Precision BioSciences Trading Up 16.5%

Shares of NASDAQ DTIL opened at $8.12 on Thursday. Precision BioSciences has a 1-year low of $3.53 and a 1-year high of $9.62. The company has a debt-to-equity ratio of 0.50, a quick ratio of 12.82 and a current ratio of 12.82. The stock’s 50-day moving average is $6.83 and its two-hundred day moving average is $6.55.

Analysts Set New Price Targets

A number of brokerages recently issued reports on DTIL. Wall Street Zen lowered Precision BioSciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. HC Wainwright reaffirmed a “buy” rating on shares of Precision BioSciences in a report on Monday, August 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Precision BioSciences in a research report on Tuesday. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Precision BioSciences currently has an average rating of “Moderate Buy” and an average target price of $32.25.

Precision BioSciences Company Profile

Precision BioSciences, Inc is a biotechnology company developing gene-editing medicines using its proprietary ARCUS platform. ARCUS is based on engineered DNA-cutting enzymes designed to make targeted changes to genetic material, with the potential to remove, insert or correct DNA sequences in human cells.

The company’s research and development activities have focused primarily on in vivo gene editing, in which therapeutic editing components are delivered directly into the body. Its development programs have included potential treatments for conditions such as chronic hepatitis B infection, Duchenne muscular dystrophy and certain rare genetic disorders.